Browsing by Subject "Drugs, Generic"

Now showing 1 - 2 of 2
  • Thumbnail Image
    ItemOpen Access
    Does generic entry always increase consumer welfare?
    (Food Drug Law J, 2012) Grabowski, Henry; Lewis, Tracy; Guha, Rahul; Ivanova, Zoya; Salgado, Maria; Woodhouse, Sally
    This article examines how the nature of competition between brands in a therapeutic category changes after generic entry and provide a framework for analyzing the effect of generic entry on consumer welfare that takes into account the generic free riding problem. It demonstrates that changes in competition along dimensions other than retail price--such as competition in research and development efforts and in promotional activities--may, in certain situations, result in generic entry having an overall negative impact on consumer welfare.
  • Thumbnail Image
    ItemOpen Access
    Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.
    (Health Aff (Millwood), 2011-11) Grabowski, Henry G; Kyle, Margaret; Mortimer, Richard; Long, Genia; Kirson, Noam
    The evolution of pharmaceutical competition since Congress passed the Hatch-Waxman Act in 1984 raises questions about whether the act's intended balance of incentives for cost savings and continued innovation has been achieved. Generic drug usage and challenges to brand-name drugs' patents have increased markedly, resulting in greatly increased cost savings but also potentially reduced incentives for innovators. Congress should review whether Hatch-Waxman is achieving its intended purpose of balancing incentives for generics and innovation. It also should consider whether the law should be amended so that some of its provisions are brought more in line with recently enacted legislation governing approval of so-called biosimilars, or the corollary for biologics of generic competition for small-molecule drugs.